FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports

The FDA is set to reverse an earlier rejection of Regenxbio's rare-disease therapy, marking a meaningful regulatory win for the company. The development is positive for the drug's approval prospects and could materially improve sentiment around Regenxbio, though the article does not specify the therapy, timing, or commercial impact.

Analysis

The FDA is set to reverse an earlier rejection of Regenxbio's rare-disease therapy, marking a meaningful regulatory win for the company. The development is positive for the drug's approval prospects and could materially improve sentiment around Regenxbio, though the article does not specify the therapy, timing, or commercial impact.